Personalized Treatment of 6-Mercaptopurine in Thai Children with Acute Lymphoblastic Leukemia
Pharmacogenetics of 6-Mercaptopurine
DOI:
https://doi.org/10.31584/psumj.2021245994Keywords:
6-mercaptopurine, lymphoblastic leukemia, TPMTAbstract
Thanks to its ability to inhibit deoxyribonucleic acid synthesis, 6-mercaptopurine (6-MP), is one of the indispensable medications for acute lymphoblastic leukemia (ALL) patients. Nevertheless, some patients may succumb to myelotoxicity, leading to treatment disruption or even life-threatening events. Owing to the advances in pharmacogenomics, the genetic polymorphism of genes regulating purine synthesis has been identified and physicians can adjust the dose of 6-MP according to each polymorphism. Such polymorphisms genetically vary among ethnicities. In this article, 2 genetic polymorphisms, namely thiopurine methyltransferase and Nudix (nucleoside diphosphate linked moiety X) type motif 15, are clinically discussed, with a special focus on the clinical studies in Thai children with ALL.
References
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improvesurvival for children and adoles cents with acute lymphobla tic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012;30:1663-9.
Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Seminars in Hematology 2013;50:185-96.
Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/Methotrexate maintenance the apy of childhood acute lymphoblastic leukemia: clinical facts and fition. J Pediatr Hematol Oncol 2014;36:503-17.
Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic lekemia: a report from the children’s oncology group. J Clin Oncol 2012;30:2094-101.
Rumbo C. Azathioprine metabolite measurements: its use in current clinical practice. Pediatr Transplant 2004;8:606-8.
Schmiegelow K, Schrøder H, Gustafsson G, Kris tinsson J, Glomstein A, Salmi T, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 1995;13:345-51.
Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:1332-9.
Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. AP&T 2020;51:1286-304.
Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblasticleukemia: results from the NOPHO ALL-92 study Blood 2009;113:6077-84.
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene l cus. J Natl Cancer Inst 1999;91:2001-8.
Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical Pharma cogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019;105:1095-105.
Cooper SC, Ford LT, Berg JD, Lewis MJ. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacoge Nomics 2008;9:303-9.
Bahari A, Hashemi M, Bari Z, Moazeni-Roodi A, Kaykhaei MA, Narouie B. Frequency of thiopurine S-methyltransferase (TPMT) alleles in southeast Iranian population. Nucleosides Nucleotides Nucleic Acids 2010;29:237-44.
Srimartpirom S, Tassaneeyakul W, Kukongviriyapan V, Tassaneeyakul W. Thiopurine S-methyltransferase genetic polymorphism in the Thai population. British J Clin Pharm 2004;58:66-70.
Hongeng S, Sasanakul W, Chuansumrit A, Pakakasama S, Chattananon A, Hathirat P. Frequency of thiopurine Smethyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol 2000;35:410-4.
Liu Y, Meng Y, Wang L, Liu Z, Li J, Dong W. Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a metaanalysis. Onco Targets Ther 2018;11:8309-17.
Yang S-K, Hong M, Baek J, Choi H, Zhao W, Jung Y, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017-20.
Buaboonnam J, Sripatanatadasakul P, Treesucon A, Glomglao W, Siraprapapat P, Narkbunnam N, et al. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia. Pediatr Int 2019;61:754-8.
Puangpetch A, Tiyasirichokchai R, Pakakasama S, Wiwattanakul S, Anurathapan U, Hongeng S, et al. NUDT15 enetic variants are related to thiopurine-induced netropenia in Thai children with acute lymphoblastic leukemia. Pharmacogenomics 2020;21:403-10.
Chiengthong K, Ittiwut C, Muensri S, Sophonphan J, Sosothikul D, Seksan P, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 2016;101:e24-e6.
Wang R, Liu B, Li J, Xu J, Wang X, Zhao Z, et al. Association between the c.415C > T, c.52G > A, and 36_37insGGAGTC polymorphisms of NUDT 15 and thiopurine-induced leukopenia, thiopurine intolerance, and severe hair loss: an updated meta-analysis. Drug Design, Development and Therapy 2019;13:2729-44.
Koutsilieri S, Caudle KE, Alzghari SK, Monte AA, Relling MV, Patrinos GP. Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango. Am J Hematol 2019;94:737-40.
Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010;63:288-95
